

Susan McCune, M.D.
Director, Office of Pediatric Therapeutics
Office of Clinical Policy and Programs
Office of the Commissioner, FDA



PEDIATRIC ADVISORY COMMITTEE OPENING REMARKS

*Pediatric Advisory Committee Meeting
September 15, 2020*

Opening Remarks

- Personnel Update
- Web-posted reviews
- Update for Montelukast (Singulair)
- Non-Compliance Letters

Personnel Update


- PAC

- Jennifer Goldman, MD



- OPT

- Sheila Reese, RN



- Ester Hatton



- Jeanine Best, MSN, RN, PNP



- CDR Margaret V. Caulk, MPH



Web Posted Reviews

- **Center for Drug Evaluation and Research (N=15)**

- BUTRANS (buprenorphine transdermal system)
- CANASA (mesalamine suppositories for rectal use)
- DESCOVY (emtricitabine and tenofovir alafenamide)
- DRAXIMAGE DTPA (technetium TC-99m pentetate kit) injection and inhalation
- DYSPORT (abobotulinumtoxinA)
- GENVOYA (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) oral tablets
- LUMASON (sulfur hexafluoride lipid-type A microspheres) injectable suspension
- LUMIFY (brimonidine tartrate) OTC
- LUZU (luliconazole) cream, 1%
- OMIDRIA (phenylephrine and ketorolac intraocular solution)
- SENSIPAR (cinacalcet)
- STELARA (ustekinumab) injection
- SYMFI LO (efavirenz 400 milligram (mg) + lamivudine 300 mg + tenofovir disoproxil fumarate 300 mg) and SYMFI (efavirenz 600 mg + lamivudine 300 mg + tenofovir disoproxil fumarate 300 mg)
- TRIUMEQ (abacavir, dolutegravir, and lamivudine)
- XEPI (ozenoxacin)

- **Center for Biologics Evaluation and Research (N=9)**

- AFSTYLA (antihemophilic factor (recombinant), single chain)
- EPICEL (cultured epidermal autografts)
- FLUCELVAX QUADRIVALENT (influenza vaccine)
- FLUCELVAX (influenza vaccine)
- FLULAVAL (influenza vaccine)
- FLULAVAL QUADRIVALENT (influenza vaccine)
- HIBERIX (Haemophilus b conjugate vaccine (tetanus toxoid conjugate))
- KOVALTRY (antihemophilic factor (recombinant))
- Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted

- **Center for Devices and Radiological Health (N=7)**

- CONTEGRA PULMONARY VALVED CONDUIT (Humanitarian Device Exemption (HDE))
- ELANA SURGICAL KIT (HDE)
- ENTERRA THERAPY SYSTEM (HDE)
- LIPOSORBER LA-15 SYSTEM (HDE)
- MEDTRONIC ACTIVA DYSTONIA THERAPY (HDE)
- PLEXIMMUNE IN-VITRO DIAGNOSTIC TEST (HDE)
- PULSERIDER ANEURYSM NECK RECONSTRUCTION DEVICE (HDE)

Medwatch Safety Alerts for Human Medical Products

<https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/default.htm>



Montelukast and Neuropsychiatric Events

- 2008: Warnings and Precautions, Drug Safety Communication, Dear Health Care Provider letters issued
 - Postmarketing reports
 - Wide variety of events, including behavior changes and completed suicide
- 2008 – 2019: Additional neuropsychiatric events included in label
- September 2019: Joint Meeting of the Pediatric Advisory Committee and the Drug Safety and Risk Mitigation Advisory Committee
 - Response to stakeholder requests
 - Review of FAERS data, published literature and results from observational study in Sentinel

Montelukast and Neuropsychiatric Events



- Re-assessed benefit-risk for asthma and allergic rhinitis
 - Benefits may not outweigh the risks for treatment of allergic rhinitis
 - New safety information
 - Nature of disease
 - Context of available therapies
- March 4, 2020: Issue safety labeling changes
 - Boxed Warning
 - Limitation of use for allergic rhinitis → reserve use for patients who have inadequate response or intolerance to alternative therapies
 - Medication Guide
 - Drug Safety Communication and Press Release



Non-Compliance Letters

- Center for Biologics Evaluation and Research (n=2)
 - <https://www.fda.gov/aboutfda/centersoffices/officeofmedicinalproductsandtobacco/cber/ucm448393.htm>
- Center for Drug Evaluation and Research (n=46)
 - <https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm343203.htm>
- The websites list the sponsor, product, a copy of the non-compliance letter, the sponsor's response (if available), and the status of the PREA requirement (e.g., released, replaced, fulfilled)

Non-Compliance Letters

- Center for Biologics Evaluation and Research (n=2)
 - No new letters since the last PAC meeting
- Center for Drug Evaluation and Research (n=46)
 - 15 new letters since the last PAC meeting

Non-Compliance Letters (CDER)



Sponsor	Product	Date of Letter	Date of Sponsor Response
Akebia Therapeutics	Auryxia (ferric citrate) Tablets	1/31/20	3/13/20
Arbor Pharmaceuticals, LLC	Edarbi (azilsartan medoxomil) Tablets, 40 mg & 80 mg	2/10/20	3/26/20
Assertio Therapeutics, Inc	Zipsor (diclofenac potassium) liquid filled-capsules)	11/5/19	12/26/19
AstraZeneca Pharmaceuticals LP	Nexium (esomeprazole magnesium) for delayed release oral suspension	8/21/19	10/3/19
Cumberland Pharmaceuticals, Inc.	Vibativ (televancin) for Injection, 250 mg & 750 mg	12/12/19	1/15/20
Ferring Pharmaceuticals, Inc.	Prepopik (citric acid, magnesium oxide, and sodium picosulfate)	10/4/19	11/19/19
Mylan Ireland Limited	Arixtra (fondaparinux sodium injection) solution	4/27/20	6/16/20